## Soft-tissue images. Proximal jejunal gastrointestinal stromal tumour

A 74-year-old man presented with a 3-month history of progress-sive abdominal pain, occasional nausea and vomiting. On physical examination, a large abdominal mass was palpated. Computed tomography showed a large mass, measuring 13 × 18 cm, with a fluid-filled centre and irregular walls (Fig. 1). The upper



FIG. 1.



FIG. 2.

aspect of the mass was indistinguishable from the inferior body of the pancreas and displaced the stomach ventrally (Fig. 2, arrow). Five days later, on repeat computed tomography and biopsy, air was noted within the lumen of the mass (Fig. 3). The patient was immediately transferred to a tertiary care hospital, where he experienced a syncopal episode followed by significant melena. He became hemodynamically unstable. His hemoglobin level dropped from 139 g/L to 91 g/L.

At operation, a centrally located large vascular tumour was found, which appeared to arise from the pancreas. When the distal pancreas and spleen were mobilized and resected with the tumour, it was apparent that the mass arose from the jejunum, 10 cm proximal to the ligament of Treitz. Dissection of the



FIG. 3.

mass revealed a cavity filled with several litres of clotted blood and air. A hole was found between the jejunum and the tumour. In retrospect, computed tomography showed that the mass was related to the jejunum (Fig. 2, arrowhead).

On pathological examination the operative specimen was found to be a malignant gastrointestinal stromal tumour arising from the proximal jejunum. The patient made a smooth recovery.

Gastrointestinal stromal tumours can grow to a large size, resulting in abdominal pain, as in this patient. About 20% of these tumours arise from the small intestine. Upper gastrointestinal bleeding is not uncommon, but perforation and bleeding between the tumour and the bowel has not been reported. These tumours have recently been shown to be commonly associated with a mutation of the *KIT* gene that may respond to the tyrosine kinase inhibitor ST1571.

## **References**

- Strickland L, Letson GD, Muro-Cacho CA. Gastrointestinal stromal tumors. Cancer Control 2001;8:252-61.
- Jeonsuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor ST1571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-6.

Submitted by Michael Cooke, MD, Michael Dunham, MD, and Francis Sutherland, MD, Department of Surgery, Peter Lougheed Hospital, University of Calgary, Calgary, Alta.

Correspondence to: Dr. Francis Sutherland, Department of Surgery, Peter Lougheed Hospital, 3500-26th Ave. NE, Calgary AB T1Y 6J4; fax 403 219-3574; Francis.Sutherland@CRHA-Health.ab.ca

Submissions to Surgical Images, soft-tissue section, should be sent to the section editors: Dr. David P. Girvan, Victoria Hospital Corporation, PO Box 5375, Station B, London ON N6A 5A5 or Dr. Nis Schmidt, Department of Surgery, St. Paul's Hospital, 1081 Burrard St., Vancouver BC V6Z 1Y6.